Editing Lung cancer (section)

==Research==

While lung cancer is the deadliest type of cancer, it receives the third-most funding from the US [[National Cancer Institute]] (NCI, the world's largest cancer research funder) behind [[brain cancer]]s and [[breast cancer]].<ref>{{cite web|url=https://www.cancer.gov/about-nci/budget/fact-book/data/research-funding |accessdate=22 April 2023 |title=Funding for Research Areas |date=10 May 2022 |publisher=National Cancer Institute}}</ref> Despite high levels of gross research funding, lung cancer funding per death lags behind many other cancers, with around $3,200 spent on lung cancer research in 2022 per US death, considerably lower than that for brain cancer ($22,000 per death), breast cancer ($14,000 per death), and cancer as a whole ($11,000 per death).<ref>{{cite web|url=https://report.nih.gov/funding/categorical-spending#/ |accessdate=30 April 2023 |title=Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) |date=31 March 2023 |publisher=US [[National Institutes of Health]]}}</ref> A similar trend holds for private [[nonprofit organization]]s. Annual revenues of lung cancer-focused nonprofits rank fifth among cancer types, but lung cancer nonprofits have lower revenue than would be expected for the number of lung cancer cases, deaths, and potential years of life lost.{{sfn|Kamath|Kircher|Benson|2019|loc="Results"}}

Despite this, many investigational lung cancer treatments are undergoing [[clinical trial]]s – with nearly 2,250 active clinical trials registered as of 2021.{{sfn|Batra|Pawar|Bahl|2021|loc="Practice Points"}} Of these, a large plurality are testing radiotherapy regimens (26% of trials) and surgical techniques (22%). Many others are testing targeted anticancer drugs, with targets including EGFR (17% of trials), [[microtubule]]s (12%), VEGF (12%), immune pathways (10%), mTOR (1%), and [[histone deacetylase]]s (<1%).{{sfn|Batra|Pawar|Bahl|2021|loc="Figure 2: Types of treatment for lung cancer in clinical trials, Phase I-IV"}}